Market Research Logo

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Summary

Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue .In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable angina (UA), myocardial infarction (MI) and/or death due to myocardial ischemia. In general, these ACS events can be viewed as the culmination of coronary artery disease (CAD), the asymptomatic build-up of atherosclerotic plaque on the walls of the coronary arteries. The triggering of an ACS event stemming from UA or MI initiates the acute phase treatment setting where therapeutic interventions are utilized to reverse and prevent the physiochemical processes that lead to coronary stenosis. Whereas, the chronic phase treatment setting involves secondary preventative measures that are used to avoid recurrent ACS events from occurring.

Highlights

Key Questions Answered

  • The new generation antiplatelets, Brilinta and Effient will see a significant increase in patient shares for the treatment ACS against the previous cornerstone, clopidogrel. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ACS market?
  • The PCSK9 inhibitors recently launched into the CV market, and these are predicted to have a notable impact in the ACS space once their CV outcomes data is shown. The most notable candidate in the current late-stage ACS pipeline is ETC-1002, which is vying to target the needed statin intolerant ACS population. Will these newly marketed and late-stage drugs make a significant impact on the ACS market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • We have seen a notable increase in the ACS population in terms of diagnosed prevalent ACS cases , as well as ACS hospitalisations (incidence and recurrent events). How will epidemiological changes impact the growth of the future market?
Key Findings
  • The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.
  • The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.
  • The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.
  • The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.
Scope
  • Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACS therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global ACS therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 ACS Diagnosed Prevalence
4.3.2 STEMI and NSTEMI Trends
4.3.3 ACS Hospitalizations
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for ACS (2015-2025)
4.5.1 Diagnosed Prevalent Cases of ACS
4.5.2 Age-Specific Diagnosed Prevalent Cases of ACS
4.5.3 Sex-Specific Diagnosed Prevalent Cases of ACS
4.5.4 Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA
4.5.5 Age-Standardized Diagnosed Prevalence of ACS
4.5.6 ACS Hospitalizations
4.5.7 Sex-Specific ACS Hospitalizations
4.5.8 ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Diagnosis
5.1.2 Treatment Guidelines and Leading Prescribed Drugs
5.1.3 Clinical Practice
5.2 US
5.3 5EU
5.4 Japan
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - Acute Coronary Syndrome
6.2.1 Antihypertensives
6.2.2 Anticoagulants
6.2.3 Fibrinolytics
6.2.4 Antidyslipidemics
6.2.5 Antiplatelets
7 Unmet Need and Opportunity
7.1 Overview
7.2 Management of ACS in Elderly Patients
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Blood Thinning Agent with Reduced Bleeding
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Achieving Guideline-Recommended Levels of LDL-C
7.5.1 Unmet need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Optimal Treatment of ACS Patients with Hyperglycemia
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.2.1 Bococizumab
8.2.2 Anacetrapib
8.2.3 CSL-112
8.2.4 CER-001
8.2.5 LY3015014
8.2.6 AMG-899
8.2.7 ETC-1002
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Amgen
9.3.2 AstraZeneca
9.3.3 Bristol-Myers Squibb
9.3.4 Cerenis Therapeutics
9.3.5 CSL Limited
9.3.6 Daiichi Sankyo
9.3.7 Eli Lilly
9.3.8 Esperion Therapeutics
9.3.9 GlaxoSmithKline
9.3.10 Janssen
9.3.11 The Medicines Company
9.3.12 Merck & Co.
9.3.13 Pfizer
9.3.14 Sanofi
10 Market Outlook
10.1 Global Market
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 United States
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 France
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Germany
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 Italy
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
10.6 Spain
10.6.1 Forecast
10.6.2 Key Events
10.6.3 Drivers and Barriers
10.7 United Kingdom
10.7.1 Forecast
10.7.2 Key Events
10.7.3 Drivers and Barriers
10.8 Japan
10.8.1 Forecast
10.8.2 Key Events
10.8.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed Acute Coronary Syndrome Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Drug Assumptions
11.4.7 Generic Erosion
11.4.8 Pricing of Pipeline Agents
11.5 Physicians and Specialists Included in this Study
11.6 About the Authors
11.6.1 Analyst
11.6.2 Therapy Area Director
11.6.3 Epidemiologist
11.6.4 Global Director of Therapy and Epidemiology
11.7 About GlobalData
11.8 Disclaimer
1.1 List of Tables
Table 1: Marketed Antiplatelet Agents that Inhibit Platelet Activation
Table 2: Marketed Anticoagulants that Inhibit the Coagulatory Cascade
Table 3: Antidyslipidemic agents
Table 4: Classifications of ACS
Table 5: Universal Classification of MI
Table 6: Symptoms of Acute Coronary Syndrome
Table 7: Risk Factors and Comorbidities for ACS
Table 8: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants
Table 9: 7MM, Sources of Diagnosed Prevalence Data for MI
Table 10: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI
Table 11: 7MM, Data Sources of ACS Hospitalizations
Table 12: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations
Table 13: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
Table 14: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015
Table 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N (Row %), 2015
Table 16: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ≥25 Years, N (Row %), 2015
Table 17: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
Table 18: 7MM, Sex-Specific ACS Hospitalizations, Ages ≥25 Years, N (Row %), 2015
Table 19: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ≥25 Years, Both Sexes, N, 2015
Table 20: Most-Prescribed Drugs for ACS by Class in the Global Markets, 2015
Table 21: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
Table 22: Country Profile for ACS - US
Table 23: Country Profile for ACS - 5EU
Table 24: Country Profile for ACS - Japan
Table 25: Leading Treatments for ACS, 2015
Table 26: Commonly Used Beta Blockers
Table 27: Product Profile - Beta Blockers
Table 28: Beta Blockers SWOT Analysis, 2015
Table 29: Global ACS Sales Forecasts [$m] for Beta Blockers, 2015-2025
Table 30: Commonly Used ACE Inhibitors
Table 31: Product Profile - ACE Inhibitors
Table 32: ACE InhibitorSWOT Analysis, 2015
Table 33 Global ACS Sales Forecasts [$m] for ACE inhibitors, 2015-2025
Table 34: Commonly Used ARBs
Table 35: Product Profile - Angiotensin Receptor Blockers (ARBs)
Table 36: ARB SWOT Analysis, 2015
Table 37: Global ACS Sales Forecasts [$m] for ARBs, 2015-2025
Table 38: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs)
Table 39: MRA SWOT Analysis, 2016
Table 40: Global ACS Sales Forecasts [$m] for MRAs, 2015-2025
Table 41: Product Profile - Warfarin
Table 42: Warfarin SWOT Analysis, 2015
Table 43: Global ACS Sales Forecasts [$m] for Warfarin, 2015-2025
Table 44: Product Profile - Angiomax
Table 45: AngiomaxSWOT Analysis, 2015
Table 46: Global ACS Sales Forecasts [$m] for Angiomax, 2015-2025
Table 47: Product Profile - Fondaparinux
Table 48: Arixtra SWOT Analysis, 2015
Table 49: Global ACS Sales Forecasts ($M) for Fondaparinux, 2015-2025
Table 50: Product Profile - Xarelto (rivaroxaban)
Table 51: Xarelto SWOT Analysis, 2015
Table 52: Global ACS Sales Forecast ($M) for Xarelto, 2015-2025
Table 53: Commonly Used tPAs
Table 54: Product Profile - Tissue Plasminogen Activator (tPA)
Table 55: FibrinolyticsSWOT Analysis, 2015
Table 56: Global ACS Sales Forecast ($M) for Fibrinolytics, 2015-2025
Table 57: Product Profile - Repatha (Evolocumab)
Table 58: Product Profile - Praluent (Alirocumab)
Table 59: PCSK9 inhibitors SWOT Analysis, 2015
Table 60: Global ACS Sales Forecasts [$m] for Repatha, 2015-2025
Table 61: Global ACS Sales Forecasts [$m] for Praluent, 2015-2025
Table 62: Product Profile - Atorvastatin
Table 63: Product Profile - Simvastatin
Table 64: Lipitor (Atorvastatin) SWOT Analysis, 2015
Table 65: Zocor (Simvastatin) SWOT Analysis, 2015
Table 66: Global ACS Sales Forecasts [$m] for Generic Statins, 2015-2025
Table 67: Product Profile - Crestor (Rosuvastatin)
Table 68: Crestor (Rosuvastatin) SWOT Analysis, 2015
Table 69: Global ACS Sales Forecasts [$m] for Crestor, 2015-2025
Table 70: Product Profile - Clopidogrel
Table 71: Clopidogrel SWOT Analysis, 2015
Table 72: Global ACS Acute Phase Sales Forecast ($M) for Clopidogrel, 2015-2025
Table 73: Global ACS Chronic Phase Sales Forecasts ($M) for Clopidogrel, 2015-2025
Table 74: Product Profile - Brilinta (ticagrelor)
Table 75: Brilinta (ticagrelor) SWOT Analysis, 2015
Table 76: Global Acute Phase ACS Sales Forecast ($M) for Brilinta, 2015-2025
Table 77: Global ACS Chronic Phase Sales Forecast ($M) for Brilinta, 2015-2025
Table 78: Product Profile - Effient (Prasugrel)
Table 79: Effient (Prasugrel) SWOT Analysis, 2015
Table 80: Global Acute Phase ACS Sales Forecast ($M) for Effient, 2015-2025
Table 81: Global ACS Chronic Phase Sales Forecast ($M) for Effient, 2015-2025
Table 82: Product Profile - Integrilin (Eptifibatide)
Table 83: Integrilin (Eptifibatide) SWOT Analysis, 2015
Table 84: Global ACS Sales Forecast ($M) for Integrilin, 2015-2025
Table 85: Product Profile - Cangrelor
Table 86: Kengreal (cangrelor) SWOT Analysis, 2015
Table 87: Global ACS Sales Forecasts ($M) for Kengreal, 2015-2025
Table 88: Product Profile - Zontivity (Vorapaxar)
Table 89: Vorapaxar SWOT Analysis, 2015
Table 90: Global ACS Sales Forecast ($M) for Zontivity, 2015-2025
Table 91: Unmet Need and Opportunity in ACS
Table 92: Comparison of Therapeutic Classes in Development for ACS, 2015
Table 93: Comparison of Therapeutic Classes in Pipeline for ACS, 2016
Table 94: Product Profile - Bococizumab (PF-04950615)
Table 95: Bococizumab (PF-04950615) SWOT Analysis, 2015
Table 96: Global ACS Sales Forecasts [$m] for Bococizumab, 2015-2025
Table 97: Product Profile - Anacetrapib
Table 98: Anacetrapib SWOT Analysis, 2015
Table 99: Global ACS Sales Forecasts [$m] for Anacetrapib, 2015-2025
Table 100: Product Profile - CSL-112
Table 101: CSL-112 SWOT Analysis, 2015
Table 102: Global ACS Sales Forecasts [$m] for CSL-112, 2015-2025
Table 103: Product Profile - CER-001
Table 104: CER-001 SWOT Analysis, 2015
Table 105: Global ACS Sales Forecasts [$m] for CER-001, 2015-2025
Table 106: Product Profile - LY3015014
Table 107: LY3015014 SWOT Analysis, 2015
Table 108 Global ACS Sales Forecasts [$m] for LY3015014 , 2015-2025
Table 109: Product Profile - AMG-899
Table 110: AMG-899 SWOT Analysis, 2015
Table 111: Global ACS Sales Forecasts [$m] for AMG-899, 2015-2025
Table 112: Product Profile - ETC-1002
Table 113: ETC-1002 SWOT Analysis, 2016
Table 114: Global ACS Sales Forecasts [$m] for ETC-1002, 2015-2025
Table 115: Key Companies in the ACS Market, 2016
Table 116: Amgen’s ACS Portfolio Assessment, 2016
Table 117: AstraZeneca’s ACS Portfolio Assessment, 2015
Table 118: BMS’s ACS Portfolio Assessment, 2015
Table 119: Cerenis’ ACS Portfolio Assessment, 2015
Table 120: CSL Limited’s ACS Portfolio Assessment, 2015
Table 121: Daiichi Sankyo’s ACS Portfolio Assessment, 2015
Table 122: Eli Lilly’s ACS Portfolio Assessment, 2015
Table 123: Esperion’s ACS Portfolio Assessment, 2016
Table 124: GlaxoSmithKline’s Acute Coronary Syndrome Portfolio Assessment, 2015
Table 125: Janssen’s ACS Portfolio Assessment, 2015
Table 126: The Medicines Company’s Acute Coronary Syndrome Portfolio Assessment, 2015
Table 127: Merck’s ACS Portfolio Assessment, 2015
Table 128: Pfizer’s ACS Portfolio Assessment, 2015
Table 129: Sanofi’s ACS Portfolio Assessment, 2015
Table 130: Global Sales Forecasts [$m] for Acute Coronary Syndrome, 2015-2025
Table 131: ACS Global market - Drivers and Barriers, 2015-2025
Table 132: Sales Forecasts [$m] for Acute Coronary Syndrome in the US, 2015-2025
Table 133: Key Events Impacting Sales for ACS in the US, 2015-2025
Table 134: US ACS Market - Drivers and Barriers, 2015-2025
Table 135: Sales Forecasts [$m] for Acute Coronary Syndrome in France, 2015-2025
Table 136: Key Events Impacting Sales for ACS in France, 2015-2025
Table 137: France ACS market - Drivers and Barriers, 2015-2025
Table 138: Sales Forecasts [$m] for Acute Coronary Syndrome in Germany, 2015-2025
Table 139: Key Events Impacting Sales for ACS in Germany, 2015-2025
Table 140: Germany ACS market - Drivers and Barriers, 2015-2025
Table 141: Sales Forecasts [$m] for Acute Coronary Syndrome in Italy, 2015-2025
Table 142: Key Events Impacting Sales for ACS in Italy, 2015-2025
Table 143: Italy ACS market - Drivers and Barriers, 2015-2025
Table 144: Sales Forecasts [$m] for Acute Coronary Syndrome in Spain, 2015-2025
Table 145: Key Events Impacting Sales for ACS in Spain, 2015-2025
Table 146: Spain ACS Market - Drivers and Barriers, 2015-2025
Table 147: Sales Forecasts [$m] for Acute Coronary Syndrome in the UK, 2015-2025
Table 148: Key Events Impacting Sales for ACS in the UK, 2015-2025
Table 149: UK ACS market - Drivers and Barriers, 2015-2025
Table 150: Sales Forecasts [$m] for Acute Coronary Syndrome in Japan, 2015-2025
Table 151: Key Events Impacting Sales for ACS in Japan, 2015-2025
Table 152: Japan ACS Market - Drivers and Barriers, 2015-2025
Table 153: Key ACS Launch Dates
Table 154: Key Patent Expiries
Table 155: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: The ACS Timeline and the Scope of GlobalData’s ACS Report and Forecast
Figure 2: Progression of CAD, Atherosclerotic Plaque Rupture, Thrombosis, and ACS
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
Figure 4: Electrocardiography in the Diagnosis of ACS
Figure 5: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008
Figure 6: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%)
Figure 7: Case Segmentation Map
Figure 8: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
Figure 9; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015
Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N, 2015
Figure 11: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ≥25 Years, N, 2015
Figure 12: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ≥25 Years, 2015
Figure 13: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
Figure 14: 7MM, Sex-Specific ACS, Ages ≥25 Years, N, 2015
Figure 15: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ≥25 Years, Both Sexes, N, 2015
Figure 16: Company Portfolio Gap Analysis in ACS, 2015-2025
Figure 17: Global Sales for ACS by Region, 2015-2025
Figure 18: Global Sales for ACS by Class, 2015-2025
Figure 19 Global Sales for PCSK9 inhibitors for ACS, 2015-2025
Figure 20: Sales for ACS in the US by Drug Class, 2015-2025
Figure 21: Sales for ACS in France by Drug Class, 2015-2025
Figure 22: Sales for ACS in Germany by Drug Class, 2015-2025
Figure 23: Sales for ACS in Italy by Drug Class, 2015-2025
Figure 24: Sales for ACS in Spain by Drug Class, 2015-2025
Figure 25: Sales for ACS in the UK by Drug Class, 2015-2025
Figure 26: Sales for ACS in Japan by Drug Class, 2015-2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report